Abstract: Compositions, methods of treatment for liver disease such as liver fibrosis, compositions, and methods for the manufacture thereof, comprising a plurality of macrophages derived from human induced pluripotent stem cells (iPSCs), wherein the macrophages are polarized to a pro-inflammatory M1 phenotype and/or an anti-inflammatory M2 phenotype. Administration reduces fibrogenic gene expression and liver disease associated histological markers. The M1 macrophages express elevated CD80, TNF-? and IL-6. The M2 macrophages express elevated CD206, CCL17, and CCL22.

Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for reducing addiction to alcohol, and for ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD), or alcohol-induced brain injury, wherein optionally the alcohol-induced brain injury comprises neuronal death and astrogliosis (reducing alcohol-induced neuronal death and astrogliosis). In alternative embodiments, provided methods for administering to the individual in need thereof a compound or composition capable of inhibiting or decreasing the expression or activity of an IL-17 or IL-17 receptor (IL-17R) or ROR?t protein, transcript and/or gene to treat or for use in: reducing addiction to alcohol; or ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD) or alcohol-induced brain injury; or, inhibiting ROR ?t to effectively block production of IL-17 cytokines and attenuate development of alcohol-induced liver fibrosis and brain damage.

Abstract: Provided are methods of treating fibrotic conditions in a subject by the identification of specific subsets of fibrogenic myofibroblasts, such as portal fibroblasts expressing mesothelin, and diagnostic methods useful for determining fibrosis, and the prognosis of fibrosis.

Abstract: The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or signal transducer and activator of transcription 3 (Stat3) and/or Janus kinase 2 (Jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27).

Abstract: Provided are methods of treating fibrotic conditions in a subject and diagnostic methods for determining fibrosis and appropriate treatments for the fibrosis by the identification of specific subsets of fibrogenic myofibroblasts.